Presentation is loading. Please wait.

Presentation is loading. Please wait.

Slide 1 for Growth for Growth IR Presentation. Slide 2 This IR Presentation contains forward-looking statements that involve risks and uncertainties.

Similar presentations


Presentation on theme: "Slide 1 for Growth for Growth IR Presentation. Slide 2 This IR Presentation contains forward-looking statements that involve risks and uncertainties."— Presentation transcript:

1 Slide 1 for Growth for Growth IR Presentation

2 Slide 2 This IR Presentation contains forward-looking statements that involve risks and uncertainties. The actual results may differ from those we project and may be affected by business environment, government regulation and legislation, financial market movement, etc. NEW Run for Growth

3 Slide 3 NEW Run for Growth  LG Life Sciences…  Products Line-up  R&D Activities  Core Values

4 Slide 4 History & Growth Pathway 1983 1994 2002 2006 2011 Bio Research NCE Research Building-upBuilding-up Gearing-upGearing-up First launch of bio- pharmaceuticals in Korea (Interferon, hGH) Strategic alliance Euvax B, Eutropin Zanidip, Eutropin Out-licensing R&D productivity Sales efficiency Global products Innovative R&D Factive, out- licensed to SB Strategic alliance with BioPartners Marketing alliance with Novartis(Korea) Caspase inhibitor, out-licensed to Gilead Bio research Acquired AN- JIN Pharm corp. GlobalCompanyGlobalCompany Target Growth Driver Mileston e Pharmaceutical business initiated NCE Research Stabilizing operation Factive, approved from US FDA Critical mass Global market presence World-class performance

5 Slide 5 Business Activities - Domestic Seoul Iksan Onsan Daejeon  Head Office: Seoul  R&D Center: Daejeon  Plants : Iksan (Pharmaceuticals, rBST) Onsan (API, Agrochemicals)  Sales Offices : 11 major cities  Total Personnel : 1,100 (R&D 30%, Sales 30% Manufacturing 30%)

6 Slide 6 Asia (36%) North America (11%) South America (29%) Middle East (11%) EU (7%) Africa (4%) 2007 Overseas Sales ($80M, 36%) Business Activities - Overseas  LGLSI(India) Personnel : 130  China Branch Personnel : 3  Global Alliances  Total 25 Products Factive Insecticide Factive Insecticide Euvax B Factive Insecticide Boostin Espogen Others Euvax B Factive Insecticide Boostin Espogen Others Euvax B Boostin Espogen Infertility Euvax B Boostin Espogen Infertility Euvax B Valtropin Factive Euvax B Valtropin Factive Boostin Euvax B Eutropin Espogen Factive Insecticide Boostin Euvax B Eutropin Espogen Factive Insecticide Infertility Euvax B Eutropin Espogen Factive Infertility Euvax B Eutropin Espogen Factive

7 Slide 7 (Bil KRW) 20062007YoY07 3Q07 4QQoQ Sales Operating income (%) Income Before Tax Net income 221.2 8.8 4.0% 9.2 5.9 256.4 25.6 10.0% 23.1 18.5 16% 191% - 151% 214% 57.3 2.2 3.8% 3.0 1.8 82.5 16.3 19.8% 11.6 10.9 44% 641% - 287% 506% (20.1) (20.2)(8.5) (3.4) (24.1) (1.2) (2.0) (1.3) (0.1) (20.6) Annual Results (Bil KRW) Quarterly Results (Bil KRW) Business Results Sales(royalties) Operating Income Sales(royalties) Operating Income

8 Slide 8 NEW Run for Growth  LG Life Sciences…  Products Line-up  R&D Activities  Core Values

9 Slide 9 Products Line-up Co-Marketing Others Slide 11 Slide 12 Slide 10 Market & Customer (Mega-trend) (Mega-trend) Increased Need for Preventive Healthcare Increased Need for Preventive Healthcare Income Level Improvement Improvement Aging Society Ex-product Portfolio Others Zanidip Euvax B Factive Hyruan Plus Eutropin Undefined TA (therapeutic area) Product-centered approach In-house R&D interest New Approach L/I In-house ’02 ’04 ’06 ‘08 ’10 20 15 10 5 1 Clearly defined TA(therapeutic area) Product line-up based on newly defined TA Market & Customer friendly Newly Defined Therapeutic Areas Newly Defined Therapeutic Areas ChronicDiseaseChronicDisease PreventiveHealthcarePreventiveHealthcare Well-beingWell-being Number of products

10 Slide 10 (Bil KRW) Intended UseFY 05FY 06FY 07Comments Cardio- vascular ZanidipHypertension(CCB)47.042.025.0Price review Xilep XLHyperlipidemia-4.56.5Launched 2Q 06 (Co)-taregHypertension(ARB)-1.09.0Launched 4Q 06 EspogenAnemia11.513.5 ArthritisHyruanplusDegenerative arthritis7.519.024.5 Total Sales66.080.078.5 - CCB : Calcium Channel Blocker - ARB : Angiotensin Ⅱ Receptor Blocker Chronic Disease

11 Slide 11 (Bil KRW) Intended UseFY 05FY 06FY 07Comments Growth Eutropin GHD(pediatric) Daily injection 31.035.037.0 Declage GHD(adult) Weekly injection --3.0Launched 1Q 07 Boostin Milk production stimulant 11.511.015.5 Infertility Follimon IVF-M, C Anovulation, ART 6.08.0 FollitropeART-0.53.0Launched 4Q 06 OtherApetrolAnorexia, Cachexia--2.5Launched 1Q 07 Total Sales48.554.569.0 Well-being - GHD : Growth Hormone Deficiency - IVF-M : HMG (human menopausal gonadotropin) - IVF-C : HCG (human chorionic gonadotropin) - ART : Assistant Reproductive Technology

12 Slide 12 (Bil KRW) Intended UseFY 05FY 06FY 07Comments Euvax BHepatitis B virus23.020.017.5 Combo Vaccines under development InfluenzaInfluenza virus5.04.05.0 (Bil KRW) Intended UseFY 05FY 06FY 07Comments Immune Diagnostics Hepatitis B/C, Malaria, AIDS, pregnancy, etc. 2.03.64.2 ELISA, POCT Molecular Diagnostics Tuberculosis, Cervical cancer, etc. --0.3 real time PCR, DNA Chip Preventive Healthcare Vaccines Diagnostics - ELISA : Enzyme-linked Immunosorbent Assay, - POCT : Point-of-care Testing - real time PCR : Polymerase Chain Reaction

13 Slide 13 Quinolone antibiotic for respiratory tract infection 1st US FDA-approved drug in Korea Indication - 5-day CAP, AECB, ABS - Excellent efficacy, better patient compliance Globalization - US : Launched in Sep. 2004 (Oscient) - Mexico (Pfizer), Canada (Abbott), EU (Menarini) : Sub-licensed by Oscient - Russia, South Africa, China, Brazil, Turkey, Middle East, etc. : Launching - CAP : Community Acquired Pneumonia, - AECB : Acute Exacerbations of Chronic Bronchitis - ABS : Acute Bacterial Sinusitis, - CMO : Contract Manufacturing Organization IntermediateFinished ProductIntended UseFY 05FY 06FY 07Comments AQPMucosta TM (Rebamipide)Gastric ulcer4.06.08.5 - CBTPletaal TM (Cilostazol)Antithrombotics1.01.21.5 API Business Factive TM CMO Business (Bil KRW)

14 Slide 14 NEW Run for Growth  LG Life Sciences…  Products Line-up  R&D Activities  Core Values

15 Slide 15 Enhancing R&D productivity Value Creation Cost Global Pharma Alliance / Outsourcing Out-licensing / Co-development Competitiv- eness Focused R&D (Outside-In) Risk Management (Open Innovation) Cardiovascular Diabetes Liver disease Degenerative arthritis Growth Anti-aging Infertility Obesity Combo-vaccine Diagnostics Market & Customer(Mega-trend) PreventiveHealthcare ChronicDisease Well-being Phase Ⅱ / Ⅲ, Phase Ⅱ / Ⅲ, Approval Approval Candidate, Candidate, Pre/Phase Ⅰ Pre/Phase ⅠTarget

16 Slide 16 ProjectPartnerTargetIntended UseStatusComments HBV-ROW/KRHBVPhase Ⅱ Caspase Gilead (GS9450) Worldwide Liver Disease Phase Ⅱ Innovative drug DPP- Ⅳ -KRDiabetesPhase Ⅱ Januvia (Merck) Galvus (Novartis) AllianceTakedaWorldwideObesityDiscovery Milestones, Research fund Takeda: CT, Commercialization Alliance Pasteur (KR) WorldwideCVSDiscovery Cost Sharing R&D Pipeline – New Chemical Entities - HBV : Hepatitis B Virus - DPP-IV : Dipeptidyl Peptidase IV - ROW : Rest Of The World

17 Slide 17 ProjectPartnerTargetIntended UseStatusComments SR-hGH BioPartnersEU Pediatric/Adult (Weekly) Phase Ⅲ Co-development -US Follitrope-ROW/KRAnovulation Phase Ⅲ Expanding claims EPO-ROW/KRAnemia Phase Ⅲ Bio-reactor SR-IFNα-KRHCV Phase Ⅱ HA Derivatives-KR Facial augmentation, Arthritis Pre- clinical DTaP-HepBKaketsukenROW/KR DTP+ Hepatitis B NDA Combo-vaccine DTwP-HepB-ROW Phase Ⅲ R&D Pipeline – Biologics - DTaP : Diphtheria, Tetanus toxoids, acellular(whole cell) Pertussis adsorbed - ROW : Rest Of The World

18 Slide 18  LG Life Sciences…  Products Line-up  R&D Activities  Core Values NEW Run for Growth

19 Slide 19 LG Way Creating value for customers Respecting Human dignity “Jeong-Do” Management No.1 LG Vision Code of Conduct Managemnet Principles LG’s vision is to become the best in its class By winning customer’s acclaim as a leader in the global market “Jeong-Do” Management is LG’s unique code of conduct that governs our management activities. The English translation of “Jeong-Do” is “the right way”. - LG serves customers with integrity - LG strives to build competence through innovation - LG provides equal opportunities for its employees - LG rewards its employees based on their capabilities and performance


Download ppt "Slide 1 for Growth for Growth IR Presentation. Slide 2 This IR Presentation contains forward-looking statements that involve risks and uncertainties."

Similar presentations


Ads by Google